The present invention relates to a sulfonamide derivative which is useful as an active ingredient of pharmaceutical preparations. The sulfonamide derivatives of the present invention have CCR3 (CC type chemokine receptor) antagonistic activity, and can be used for the prophylaxis and treatment of diseases associated with CCR3 activity, in particular for the treatment of asthma, atopic dermatitis, allergic rhinitis and other inflammatory/immunological disorders.

Claim:

The invention claimed is:

1. A compound of the formula (I), its tautomeric or stereoisomeric form, or a physiologically acceptable salt thereof: ##STR00322## X represents phenyl, which issubstituted by 0 to 5 substituents independently selected from the group consisting of R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.0, or pyridine, which is substituted by 0 to 5 substituents independently selected from the group consisting of R.sup.1,R.sup.2, R.sup.3 and R.sup.4 wherein R.sup.1 is hydrogen, halogen, hydroxy, straight- or branched-C.sub.1-6 alkyl optionally substituted by mono, di, or tri halogen, straight- or branched-C.sub.1-6 alkoxy, straight- or branched-C.sub.1-6 alkoxy carbonyl,amino, straight- or branched-C.sub.1-6 alkylamino, di(straight- or branched-C.sub.1-6 alkyl)amino, straight- or branched-C.sub.1-6 alkanoyl, nitro, or phenyl, R.sup.2 is hydrogen, halogen, straight- or branched-C.sub.1-6 alkyl optionally substituted bymono, di or tri halogen, straight- or branched-C.sub.1-6 alkoxy, or cyano, or R.sup.1 and R.sup.2 together form benzene ring or C.sub.5-8 cycloalkyl fused to the adjacent phenyl or pyridine, R.sup.3 is hydrogen, halogen, or straight- orbranched-C.sub.1-6 alkyl, R.sup.4 is hydrogen, halogen, or straight- or branched-C.sub.1-6 alkyl, R.sup.0 is hydrogen, halogen, or straight- or branched-C.sub.1-6 alkyl, Y represents O, NH, NCH.sub.3, S, or S(O); Z.sup.1 represents CH or N; Z.sup.2represents CH or N; with the proviso that both Z.sup.1 and Z.sup.2 cannot be N at the same time; R.sup.5 represents halogen, nitro, or cyano, wherein q represents an integer selected from 0 to 6, R.sup.51 and R.sup.52 are independently selected fromthe group consisting of hydrogen, straight- or branched-C.sub.1-6 alkyl optionally substituted by cyano or carbamoyl and tetrazolyl optionally substituted by C.sub.1-6 alkylnitrile, or R.sup.51 and R.sup.52 may form, together with the adjacent N, asaturated 5 to 8 membered ring optionally interrupted by NH, R.sup.6 represents hydrogen, halogen, straight or branched C.sub.1-6 alkyl optionally mono-, di-, or tri-substituted by halogen, or by straight or branched C.sub.1-6 alkoxy, or R.sup.5 andR.sup.6 may form a pyrrole ring fused to adjacent phenyl, or pyridine; and R.sup.7 represents ##STR00323## wherein R.sup.72 is hydrogen, or straight- or branched-C.sub.1-6 alkyl; R.sup.73 is hydrogen, or straight- or branched-C.sub.1-6 alkyl, R.sup.74is hydrogen, or straight- or branched-C.sub.1-6 alkyl optionally substituted by phenyl, or R.sup.73 and R.sup.74 may form, together with adjacent N atom, a 5 to 8 membered saturated ring optionally substituted by C.sub.1-6 alkyl and optionallyinterrupted by NH or O; and R.sup.75 is straight- or branched-C.sub.1-6 alkylene; or a 3 to 8 membered saturated or unsaturated carbocyclic or heterocyclic ring.

2. The compound of the formula (I), its tautomeric or stereoisomeric form, or a physiologically acceptable salt thereof as claimed in claim 1, wherein R.sup.5 is chloro, iodo, nitro, or cyano; and R.sup.6 is hydrogen.

3. The compound of the formula (I), its tautomeric or stereoisomeric form, or a physiologically acceptable salt thereof as claimed in claim 1, wherein R.sup.1 is halogen, or straight- or branched-C.sub.1-6 alkyl optionally mono-, di-, ortri-substituted by halogen; R.sup.2 is halogen, or straight- or branched-C.sub.1-6 alkyl optionally mono-, di-, or tri-substituted by halogen; R.sup.3 is hydrogen; R.sup.4 is hydrogen; R.sup.0 is hydrogen; Y is O, NH, NCH.sub.3, S, or S(O); R.sup.5is halogen, nitro, or cyano; R.sup.6 is hydrogen; and R.sup.7 represents ##STR00324## wherein R.sup.72 is hydrogen, or straight- or branched-C.sub.1-6 alkyl; R.sup.73 is hydrogen, or straight- or branched-C.sub.1-6 alkyl, R.sup.74 is hydrogen, orstraight- or branched-C.sub.1-6 alkyl optionally substituted by phenyl, or R.sup.73 and R.sup.74 may form, together with adjacent N atom, a 5 to 8 membered saturated ring optionally substituted by C.sub.1-6 alkyl and optionally interrupted by NH or O; and R.sup.75 is straight- or branched-C.sub.1-6 alkylene; or a 3 to 8 membered saturated or unsaturated carbocyclic or heterocyclic ring.

4. The compound of the formula (I), its tautomeric or stereoisomeric form, or a physiologically acceptable salt thereof as claimed in claim 1, wherein R.sup.1 and R.sup.2 are identical or different and represent chloro, or methyl; R.sup.3 ishydrogen or fluoro; R.sup.4 is hydrogen; R.sup.0 is hydrogen; Y is O, NH, NCH.sub.3, S, or S(O); R.sup.5 is chloro, iodo, nitro, or cyano; R.sup.6 is hydrogen; and R.sup.7 represents ##STR00325## wherein R.sup.72 is hydrogen, or straight- orbranched-C.sub.1-6 alkyl; R.sup.73 is hydrogen, or straight- or branched-C.sub.1-6 alkyl, R.sup.74 is hydrogen, or straight- or branched-C.sub.1-6 alkyl optionally substituted by phenyl, or R.sup.73 and R.sup.74 may form, together with adjacent N atom,a 5 to 8 membered saturated ring optionally substituted by C.sub.1-6 alkyl and optionally interrupted by NH or O; and R.sup.75 is straight- or branched-C.sub.1-6 alkylene; or a 3 to 8 membered saturated or unsaturated carbocyclic or heterocyclic ring.

6. A compound of the formula (I-2), its tautomeric or stereoisomeric form, or a physiologically acceptable salt thereof: ##STR00327## wherein R.sup.1 is hydrogen, halogen, straight- or branched-C.sub.1-6 alkyl optionally substituted by mono, dior tri halogen, straight- or branched-C.sub.1-6 alkoxy, straight- or branched-C.sub.1-6 alkoxy carbonyl, amino, straight- or branched-C.sub.1-6 alkylamino, di(straight- or branched-C.sub.1-6 alkyl)amino, straight- or branched-C.sub.1-6 alkanoyl, ornitro, R.sup.2 is hydrogen, halogen, straight- or branched-C.sub.1-6 alkyl optionally substituted by mono, di or tri halogen, straight- or branched-C.sub.1-6 alkoxy, or cyano, or R.sup.1 and R.sup.2 may form benzene ring or C.sub.5-8 cycloalkyl fused tothe adjacent phenyl; R.sup.3 is hydrogen or halogen, Y represents O, NH, NCH.sub.3, S, S(O), or SO.sub.2; R.sup.5 is hydrogen, halogen, hydroxy, straight- or branched-C.sub.1-6 alkyl optionally mono-, di-, or tri-substituted by halogen or by hydroxy,straight- or branched-C.sub.1-6 alkoxy, straight- or branched-C.sub.1-6 alkoxycarbonyl, amino, straight- or branched-C.sub.1-6 alkanoylamino, phenyl-(CH.sub.2).sub.q-carbonylamino, straight- or branched-C.sub.1-6 alkylbenzoylamino, naphthylcarbonylamino,thenoylamino, nitro, cyano, carboxy, straight- or branched-C.sub.1-6 alkyl sulfonyl, oxazolidinonyl, or substituents represented by the formula, --SO.sub.2--NR.sup.51R.sup.52, or --CO--NR.sup.51R.sup.52 wherein q represents an integer selected from 0 to6, R.sup.51 and R.sup.52 are independently selected from the group consisting of hydrogen, straight- or branched-C.sub.1-6 alkyl optionally substituted by cyano or carbamoyl, tetrazolyl optionally substituted by C.sub.1-6 alkylnitrile, or R.sup.51 andR.sup.52 may form, together with the adjacent N, a saturated 5 to 8 membered ring optionally interrupted by NH, R.sup.6 is hydrogen, halogen, straight or branched C.sub.1-6 alkyl optionally mono-, di-, or tri-substituted by halogen, or by straight orbranched C.sub.1-6 alkoxy, or R.sup.5 and R.sup.6 may form a pyrrole ring fused to adjacent phenyl, or pyridine; and R.sup.7 represents ##STR00328## wherein R.sup.72 is hydrogen, or straight- or branched-C.sub.1-6 alkyl; R.sup.73 is hydrogen, orstraight- or branched-C.sub.1-6 alkyl, R.sup.74 is hydrogen, or straight- or branched-C.sub.1-6 alkyl, or R.sup.73 and R.sup.74 may form, together with adjacent N atom, a 5 to 8 membered saturated ring optionally interrupted by NH or O; and R.sup.75 isstraight- or branched-C.sub.1-6 alkylene or a 3 to 8 membered saturated or unsaturated ring.

7. The compound of the formula (I-2), its tautomeric or stereoisomeric form, or a physiologically acceptable salt thereof as claimed in claim 6, wherein R.sup.5 is chloro, iodo, nitro, or cyano; and R.sup.6 is hydrogen.

8. The compound of the formula (I-2), its tautomeric or stereoisomeric form, or a physiologically acceptable salt thereof as claimed in claim 6, wherein R.sup.1 is hydrogen, halogen, or straight- or branched-C.sub.1-6 alkyl optionally mono-,di-, or tri-substituted by halogen; R.sup.2 is hydrogen, halogen, or straight- or branched-C.sub.1-6 alkyl optionally mono-, di-, or tri-substituted by halogen; R.sup.3 is hydrogen or halogen, Y is O, NH, NCH.sub.3, S, S(O), or SO.sub.2; R.sup.5 ishalogen, nitro, or cyano; R.sup.6 is hydrogen; and R.sup.7 represents ##STR00329## wherein, R.sup.72 is hydrogen, or straight- or branched-C.sub.1-6 alkyl; R.sup.73 is hydrogen, or straight- or branched-C.sub.1-6 alkyl, R.sup.74 is hydrogen, orstraight- or branched-C.sub.1-6 alkyl, or R.sup.73 and R.sup.74 may form, together with adjacent N atom, a 5 to 8 membered saturated ring optionally interrupted by NH or O; and R.sup.75 is straight- or branched-C.sub.1-6 alkylene or a 3 to 8 memberedsaturated or unsaturated ring.

9. The compound of the formula (I-2), its tautomeric or stereoisomeric form, or a physiologically acceptable salt thereof as claimed in claim 6, wherein R.sup.1, R.sup.2 and R.sup.3 are independently selected from the group consisting ofhydrogen, chloro, and methyl; Y is O, NH, NCH.sub.3, S, S(O), or SO.sub.2; R.sup.5 is chloro, iodo, nitro, or cyano; R.sup.6 is hydrogen; and R.sup.7 represents ##STR00330## wherein R.sup.72 is hydrogen, or straight- or branched-C.sub.1-6 alkyl; R.sup.73 is hydrogen, or straight- or branched-C.sub.1-6 alkyl, R.sup.74 is hydrogen, or straight- or branched-C.sub.1-6 alkyl, or R.sup.73 and R.sup.74 may form, together with adjacent N atom, a 5 to 8 membered saturated ring optionally interrupted byNH or O; and R.sup.75 is straight- or branched-C.sub.1-6 alkylene or a 3 to 8 membered saturated or unsaturated ring.

10. The compound of the formula (I-2), its tautomeric or stereoisomeric form, or a physiologically acceptable salt thereof as claimed in claim 6, wherein R.sup.1 is halogen, or straight- or branched-C.sub.1-6 alkyl optionally mono-, di-, ortri-substituted by halogen; R.sup.2 is halogen, or straight- or branched-C.sub.1-6 alkyl optionally mono-, di-, or tri-substituted by halogen; R.sup.3 is hydrogen or fluoro; Y is O, NH, NCH.sub.3, S, S(O), or SO.sub.2; R.sup.5 is hydrogen, fluoro,chloro, bromo, iodo, trifluoromethyl, hydroxy, methoxy, amino, acetylamino, isobutylcarbonylamino, tert-butylcarbonylamino, benzoylamino, benzylcarbonylamino, phenethylcarbonylamino, methylbenzoylamino, naphthylcarbonylamino, thenoylamino, nitro, cyano,methylsulfonyl, dimethyaminosulfonyl, piperazinosulfonyl, dimethyaminocarbonyl, or piperazinocarbonyl; R.sup.6 is hydrogen, methyl, or methoxy; or R.sup.5 and R.sup.6 may form a pyrrole ring fused to adjacent phenyl; and R.sup.7 represents##STR00331## wherein R.sup.72 is hydrogen, methyl, or ethyl; R.sup.73 is hydrogen, or methyl, R.sup.74 is hydrogen, methyl, or ethyl, or R.sup.73 and R.sup.74 may form, together with adjacent N atom, piperidino, morpholino, or pyrrolidino; and R.sup.75is phenyl.